CHMP OK Puts Merck KGaA's Cladribine Pill On EU Home Stretch After Long Trek
Merck of Germany's oral multiple sclerosis medicine cladribine looks set to finally get EU approval. But the long, slow race it has had to endure - and time lost getting there - may curb sales.
You may also be interested in...
Pfizer will anchor the final week of major biopharma earnings calls, facing the same question as every firm with massive stockpiles of cash: When are you going to spend that money on a transformative M&A deal?
Germany's Merck Group plans to bolster its biopharma R&D activities in Britain - despite Brexit - on grounds the UK is too key and dynamic a player in the life sciences sphere not to - and because the conglomerate needs to be there to help ensure its evolution into a top oncology and immuno-oncology innovator.
Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.